Wave Life Sciences (WVE) Operating Leases (2019 - 2026)

Wave Life Sciences (WVE) has 8 years of Operating Leases data on file, last reported at $40.1 million in Q2 2026.

• Quarterly Operating Leases rose 195.26% year-over-year to $40.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.1 million (up 195.26% YoY) and the FY2025 annual result came in at $9.4 million, down 47.06% from the prior year.
• Operating Leases rose to $40.1 million in Q2 2026, from $7.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $40.1 million in Q2 2026 to a low of $7.4 million in Q1 2026.
• A 5-year average of $21.9 million and a median of $22.7 million in 2024 frame the typical range for Operating Leases.
• The widest YoY moves for Operating Leases: up 195.26% in 2026, down 52.99% in 2026.
• Tracing WVE's Operating Leases over 5 years: stood at $32.1 million in 2022, then decreased by 20.9% to $25.4 million in 2023, then sank by 30.07% to $17.8 million in 2024, then sank by 47.06% to $9.4 million in 2025, then jumped by 326.18% to $40.1 million in 2026.
• The last three Operating Leases figures came in at $40.1 million (Q2 2026), $7.4 million (Q1 2026), and $9.4 million (Q4 2025), per Business Quant data.